Early-phase oncology trials can face sudden and significant challenges—particularly for small biotech sponsors with limited internal resources.
When unexpected delays threaten development timelines and company viability, sponsors must act quickly, adapt trial strategy, and maintain scientific and operational momentum. The focus shifts from rigid execution to flexible, CRO-led problem solving that protects trial integrity while accelerating access to meaningful data.
Read our guide to explore more about:
- How flexible study design enabled rapid adaptation in a Phase I/II RCC trial
- How a sister study approach minimized delays and preserved development timelines
- How streamlined feasibility and site activation accelerated trial launch
- How strategic CRO support helped a small biotech generate critical early data